Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/articles/2026-08-04/eli-lilly-ripe-for-stock-split-after-obesity-drug-fueled-rally)